¿Antex Biologics Inc., of Gaithersburg, Md., said it signed a cooperative research and development agreement with the U.S. Navy that provides Navy funding for the completion of Antex's clinical development of Campyvax, a vaccine against gastroenteritis, diarrhea and traveler's disease caused by the common bacteria campylobacter. The Navy will fund clinical trials on the vaccine through Phase III in exchange for a supply of vaccine.

¿ArQule Inc., of Woburn, Mass., said it entered a microchemistry technology evaluation and chemistry services agreement with Nanoscale Combinatorial Synthesis Inc. (Nanosyn), of Tucson, Ariz., that will allow ArQule to evaluate Nanosyn's Accelerated Nanoscale Synthesis Technology system. ArQule will fund the project for up to two years.

¿BioPulse International Inc., of South Jordan, Utah, acquired exclusive intellectual property rights to PGM, a plant-derived anti-angiogenesis product, to study its effects on cancer patients.

No Comments